Molecular barriers to xenotransplantation

Transplantation

Volumn 62, Issue 3, 1996, Pages 303-310

  Lawson, Jeffrey H ^a   Platt, Jeffrey L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; GRAFT REJECTION; HISTOINCOMPATIBILITY; HUMAN; IMMUNOGLOBULIN DEPOSITION; IMMUNOPATHOGENESIS; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVIEW; XENOTRANSPLANTATION;

EID: 0029839492     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199608150-00001     Document Type: Review

References (62)

1. Platt JL, Bach FH. The barrier to xenotransplantation. Transplantation 1991; 52: 937.
2. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2: 550.
3. Perper RJ, Najarian JS. Experimental renal heterotransplantation. I. In widely divergent species. Transplantation 1966; 4: 377.
4. Hammer C. Experimental xenotransplantation between closely related nonprimate species. In: Cooper DKC, Kemp E, Reemtsma K, White DJG, eds. Xenotransplantation. The transplantation of organs and tissues between species. New York: Springer-Verlag, 1991: 339.
5. Hammer C, Suckfull M, Saumweber D. Evolutionary and immunological aspects of xenotransplantation. Transplant Proc 1992; 24: 2397.
6. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450.
7. Collins BH, Cotterell AH, McCurry KR, et al. Cardiac xenografts between primate species provide evidence for the importance of the a-galactosyl determinant in hyperacute rejection. J Immunol 1995; 154: 5500.
8. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423.
9. Parker W, Saadi S, Lin SS, Holzknecht ZE, Bustos M, Platt JL. Transplantation of discordant xenografts: a challenge revisited. Immunol Today (in press).
10. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
11. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157.
12. Kaplon RJ, Michler RE, Xu H, Kwiatkowski PA, Edwards NM, Platt JL. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1994; 59: 1.
13. Good AH, Cooper DKC, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992; 24: 559.
14. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Antipig IgM antibodies in human serum react predominantly with Galα(1,3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
15. Collins BH, Parker WR, Platt JL. Characterization of porcine endothelial cell determinants recognized by human natural antibodies. Xenotransplantation 1994; 1: 36.
16. Galili U, Swanson K. Gene sequences suggest inactivation of α-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA 1991; 88: 7401.
17. Galili U, Shohet SB, Kobrin E, Stults CLM, Macher BA. Man, apes, and old world monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263: 17755.
18. Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-α-galactosyl IgG: the specific recognition of α(1-3)-linked galactose residues. J Exp Med 1985; 162: 573.
19. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal α1-3Gal epitope in primates. Proc Natl Acad Sci USA 1987; 84: 1369.
20. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 1984; 160: 1519.
21. Platt JL, Lindman BJ, Geller RL, et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991; 52: 1037.
22. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363.
23. Parker WR, Bruno D, Holzknecht ZE, Platt JL. Xenoreactive natural antibodies: isolation and initial characterization. J Immunol 1994; 153: 3791.
24. Magee JC, Collins BH, Harland RC, et al. Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96: 2404.
25. Platt JL. Hyperacute xenograft rejection. Austin, TX: RG Landes, 1995.
26. Gewurz H, Clark DS, Cooper MD, Varco RL, Good RA. Effect of cobra venom-induced inhibition of complement activity on allograft and xenograft rejection reactions. Transplantation 1967; 5: 1296.
27. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
28. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363.
29. Brauer RB, Baldwin WM III, Daha MR, Pruitt SK, Sanfilippo F. Use of Co-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151: 7240.
30. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825.
31. Johnston PS, Wang M-W, Lim SML, Wright LJ, White DJG. Discordant xenograft rejection in an antibody-free model. Transplantation 1992; 54: 573.
32. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530.
33. White D, Wallwork J. Xenografting: probability, possibility, or pipe dream? Lancet 1993; 342: 879.
34. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
35. Kooyman DL, Byrne GW, McClellan S, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995; 269: 89.
36. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; ii: 662.
37. Diamond LE, McCurry KR, Oldham ER, et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996; 61: 1241.
38. Saadi S, Platt JL. Transient perturbation of endothelial integrity induced by antibodies and complement. J Exp Med 1995; 181: 21.
39. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213.
40. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune system-blood vessel interactions. Immunol Today 1993; 14: 500.
41. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809.
42. Leventhal JR, Matas AJ, Sun LH, et al. The immunopathology of cardiac xenograft rejection in the guinea pig to rat model. Transplantation 1993; 56: 1.
43. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797.
44. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124.
45. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67.
46. Prydz H, Pettersen KS. Synthesis of thromboplastin (tissue factor) by endothelial cells. Haemostasis 1988; 18: 215.
47. Saadi S, Holzkhecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995; 182: 1807.
48. Fries JWU, Williams AJ, Atkins RC, Newman W, Lipscomb MF, Collins T. Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am J Pathol 1993; 143: 725.
49. Bustos M, Saadi S, Platt JL. Modulation of endothelial metabolism by xenogenic serum: implications for vasoconstriction and permeability. Transplant Proc 1996; 28: 624.
50. Esmon CT. The regulation of natural anticoagulant pathways. Science 1990; 235: 1348.
51. Lawson JH, Daniels LJ, Platt JL. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc (in press).
52. Cotterell AH, Collins BH, Parker W, Harland RC, Platt JL. The humoral immune response in humans following cross-perfusion of porcine organs. Transplantation 1995; 60: 861.
53. Thompson C. Humanised pigs hearts boost xenotransplantation. Lancet 1995; 346: 766.
54. Chopek MW, Simmons RL, Platt JL. ABO incompatible renal transplantation: initial immunopathologic evaluation. Transplant Proc 1987; 19: 4553.
55. Alexandre GPJ, Squifflet JP, De Bruyere M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19: 4538.
56. Alexandre GPJ, Gianello P, Latinne D, et al. Plasmapheresis and splenectomy in experimental renal xenotransplantation. In: Hardy MA, ed. Xenograft 25. New York: Elsevier Science Publishers, 1989: 259.
57. Fischel RJ, Matas AJ, Platt JL, et al. Cardiac xenografting in the pig to rhesus model; manipulation of anti-endothelial antibody prolongs survival. J Heart Lung Transplant 1992; 11: 965.
58. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today 1996; 17: 86.
59. Inverardi L, Samaja M, Motterlini R, Mangili F, Bender JR, Pardi R. Early recognition of a discordant xenogeneic organ by human circulating lymphocytes. J Immunol 1992; 149: 1416.
60. Malyguine AM, Platt JL, Saadi S, Dawson JR. Human natural killer cells induce morphologic changes in porcine endothelial cell monolayers. Transplantation 1996; 61: 161.
61. Murray AG, Khodadoust MM, Pober JS, Bothwell ALM. Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity 1994; 1: 57.
62. Yamada K, Sachs DH, DerSimonian H. Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J Immunol 1995; 155: 5249.